You Searched For: Enzo Life Sciences

Supplier: Enzo Life Sciences

Description: The tyrphostins are well known tyrosine kinase inhibitors. However, tyrphostin 8 has been shown to inhibit calcineurin (IC50=21 µM) while displaying weak inhibition of EGFR tyrosine kinase (IC50=560 µM).

Supplier: Enzo Life Sciences

Description: The tumor suppressor CYLD is a deubiquitinylating enzyme (DUB) that antagonises NF-κB and JNK signaling by disassembly of Lys63-linked ubiquitin chains synthesised in response to cytokine stimulation. The DUB activity of CYLD is mediated by its C-terminal ubiquitin specific protease (USP) domain, pathogenic truncations and mutations of which are associated with the hypertrophic skin tumor cylindromatosis through disruption of the USP domain and subsequent loss of CYLD catalytic activity.

Supplier: Enzo Life Sciences

Description: The proteasome is widely recognised as the central enzyme of non-lysosomal protein degradation. It is responsible for intracellular protein turnover and it is also critically involved in many regulatory processes and, in higher eukaryotes, in antigen processing. The 26S proteasome is the key enzyme of the ubiquitin/ATP-dependent pathway of protein degradation. The catalytic core of this unusually large (2000kDa, 450Å in length) complex is formed by the 20S proteasome, a barrel shaped structure shown by electron microscopy to comprise of four rings each containing seven subunits. 20S Proteasomes degrade only unfolded proteins in an energy-independent manner, whereas 26S proteasomes degrade native and ubiquitinylated proteins in an ATP-dependent manner. The native protein substrates are recognised by subunits, some with ATP binding sites, of the outer 19S caps of the 26S proteasome.A second activator which can associate with the 20S proteasome in the absence of ATP is known as PA28 or the 11S regulator. The pure PA28 activator is a complex of two alternating subunits, PA28α and PA28β, which share approximately 50% homology but also show considerable similarity (30-40%) to a nuclear protein of unknown function, the Ki autoantigen (now referred to as PA28γ). These subunits, with an apparent relative molecular weight of approximately 29kDa, form ringlike heteromeric complexes of ~200kDa possibly with an α3β3 stoichiometry. Electron microscopic studies have shown PA28 to be a ring shaped particle which, like the 19S, caps the 20S proteasome, by binding to the α-rings, at both or either end. The complex may, however, be readily dissociated. The finding that PA28 modulates the proteasome-catalysed production of antigenic peptides presented to the immune system on MHC class I molecules indicates a cellular function of this activator in antigen processing.

Supplier: Enzo Life Sciences

Description: PP2A inhibitor

Supplier: Enzo Life Sciences

Description: Highly selective plasma kallikrein inhibitor (Ki = 0.81 µM). Can be used for affinity purification of kalikrein. Suppresses collagen-induced arthritis in a mouse model. Synergizes with NO donors producing antithrombotic effects ex vivo.

Supplier: Enzo Life Sciences

Description: Caspase inhibitor

Supplier: Enzo Life Sciences

Description: Host: Rabbit

Catalog Number: (89162-776)

Supplier: Enzo Life Sciences

Description: Host: Mouse, Isotype: IgG2b

Supplier: Enzo Life Sciences

Description: The diffusible free radical gas nitric oxide (NO) affects a variety of physiological functions, and is a key regulator of the cardiovascular, nervous, and immune systems. NO is synthesized in many tissues from L-arginine, oxygen, and NADPH by three known isoforms of a heme-containing flavoprotein termed NO synthase (nNOS/NOS-I, iNOS/NOS-II, and eNOS/NOS-III). nNOS is a constitutively expressed neuronal NOS isoform that exits in its latent form until it is activated by the binding of calmodulin follo wing elevation of intracellular calcium levels. The C-terminus of nNOS contains a conserved serine residue, Ser1417, analogous to Ser1177 of the constitutively expressed endothelial NOS isoform (eNOS). Phosphorylation of Ser1417 is believed to regulate nNOS activation, particularly in glucose-sensing neurons, where inhibition of AMPK pathways by glucose and leptin serve to suppress nNOS activity, whereas activation of AMPK by insulin leads to nNOS activation.

Supplier: Enzo Life Sciences

Description: α-Synuclein accumulates in Lewy bodies, which are intraneuronal cytoplasmic inclusions present in the brains of sporadic Parkinson's disease patients, and is implicated in the pathogenesis of Parkinson's disease and related neurodegenerative disorders. α-Synuclein appears to associate with other proteins that aggregate and is found in β-amyloid plaques and neuritic tangles in Alzheimer's disease.

Catalog Number: (89164-070)

Supplier: Enzo Life Sciences

Description: Produced in insect cells.

Supplier: Enzo Life Sciences

Description: Produced in E. coli.

Catalog Number: (89163-956)

Supplier: Enzo Life Sciences

Catalog Number: (89164-416)

Supplier: Enzo Life Sciences

Description: Highly active

Catalog Number: (89164-288)

Supplier: Enzo Life Sciences

Description: Produced in insect cells. Complex of human full length p110a and p85a subunits of phosphatidylinositol 3-kinase.

Supplier: Enzo Life Sciences

Description: P62, also known as Sequestosome I, is a 62kDa, 440 amino acid protein, initially identified as a ligand of the SH2 domain of p56lck, now known to be expressed in many tissues. In addition to TRAF6, PEST and zinc finger motifs, p62 has a C-terminal ubiquitin binding association (UBA) domain with an affinity for multi-ubiquitin chains, and it is considered to serve as a scaffold protein, capable of binding to multiple signalling molecules and uniting receptor-mediated signalling events with ubiquitinylation. Elevated levels of p62 have been reported in breast tumours and in alcoholic liver disease where p62 has been shown to be involved in the formation of Mallory bodies. Several mutations in the p62 UBA domain have been identified and the etiology of Paget’s disease of bone has been linked to one such mutation. Kuusisto and colleagues have demonstrated that p62 is also present in elevated levels in the hallmark inclusions found in various neurodegenerative conditions, including tauopathies (Alzheimer’s disease, Picks disease, and frontotemporal dementia) and synucleinopathies (Parkinson’s disease, dementia with Lewy body disease and multiple system atrophy). In recent years ubiquitin immunostaining has been used to provide adjunct information for neuropathological diagnosis, but it is becoming evident that p62 may be an even more reliable marker of neurodegenerative disease inclusion detection than tau, alpha-synuclein or ubiquitin immunostaining.